人工肝血液净化系统应用于重型、危重型新型冠状病毒肺炎治疗的专家共识

国家感染性疾病临床医学研究中心, 传染病诊治国家重点实验室

doi:10.3969/j.issn.1001-5256.2020.06.008

人工肝血液净化系统应用于重型、危重型新型冠状病毒肺炎治疗的专家共识

DOI: 10.3969/j.issn.1001-5256.2020.06.008

国家感染性疾病临床医学研究中心, 传染病诊治国家重点实验室

基金项目:

国家重点研发计划“新型冠状病毒感染的肺炎疫情应急项目”(2020YFC0844300);“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项(2017ZX10203201)；浙江省重点研发计划(2020C03123)

详细信息

中图分类号: R563.1
计量
- 文章访问数: 905
- HTML全文浏览量: 22
- PDF下载量: 190
- 被引次数: 0
出版历程
- 出版日期: 2020-06-20

Expert consensus on the application of artificial liver blood purification system in the treatment of severe and critical COVID-19

National Clinical Research Center for Infectious DiseasesState Key Laboratory for Diagnosis and Treatment of Infectious Diseases

Research funding:

摘要

摘要:
全国新型冠状病毒肺炎（COVID-19）的防治工作进入攻坚阶段,重型、危重型患者的有效救治是降低该疾病病死率的关键。人工肝血液净化系统能清除炎症因子,减轻炎症反应对机体的损伤,对重型、危重型患者的救治具有重要价值。由李兰娟院士领衔,基于全国各地的救治经验,整合全国各地专家意见,针对人工肝治疗重型、危重型COVID患者的基本原理、治疗适应证、相对禁忌证、治疗模式选择、监测指标及疗效评价等进行总结,制定了本专家共识,供各单位参考开展救治工作。
- 冠状病毒感染 /
- 肝,人工 /
- 新型冠状病毒肺炎 /
- 共识
Abstract:
The prevention and treatment of COVID-19 nationwide has entered a tackling phase. Effective treatment of severe and critically ill patients is the key to reducing the fatality of the disease. The artificial liver blood purification system can remove inflammatory factors,alleviate the damage of the inflammatory response to the body,and has important value for the treatment of severe COVID-19. Led by academician Li Lanjuan,based on the experience of treating patients across the country,integrating the opinions of experts from all over the country,the center summarized and formulated the consensus including the basic principles,treatment indications,relative contraindications,mode selection,monitoring indicators,and efficacy evaluation of artificial liver,which provides reference for treatment of severe COVID-19 patients.
- coronavirus infections /
- liver,artificial /
- coronavirus disease 2019 /
- consensus

HTML全文

参考文献(11)

[1] MUNSTER VJ,KOOPMANS M,van DOREMALEN N,et al. A novel coronavirus emerging in China-key questions for impact assessment[J]. N Engl J Med,2020,382(8):692-694.

[2] WONG CK,LAM CW,WU AK,et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome[J]. Clin Exp Immunol,2004,136(1):95-103.

[3] HUI DSC,ZUMLA A. Severe acute respiratory syndrome:Historical,epidemiologic,and clinical features[J]. Infect Dis Clin North Am,2019,33(4):869-889.

[4] MAHALLAWI WH,KHABOUR OF,ZHANG Q,et al. MERS-Co V infection in humans is associated with a pro-inflammatory Th1and Th17 cytokine profile[J]. Cytokine,2018,104:8-13.

[5] de JONG MD,SIMMONS CP,THANH TT,et al. Fatal outcome of human influenza A(H5N1)is associated with high viral load and hypercytokinemia[J]. Nat Med,2006,12(10):1203-1207.

[6] GUO J,HUANG F,LIU J,et al. The serum profile of hypercytokinemia factors identified in H7N9-infected patients can predict fatal outcomes[J]. Sci Rep,2015,5:10942.

[7] SADEGHI M,DANIEL V,WANG H,et al. Plasmapheresis adjusts inflammatory responses in potential kidney transplant recipients[J]. Transplantation,2013,95(8):1021-1029.

[8] LIU X,ZHANG Y,XU X,et al. Evaluation of plasma exchange and continuous veno-venous hemofiltration for the treatment of severe avian influenza A(H7N9):A cohort study[J]. Ther Apher Dial,2015,19(2):178-184.

[9] GAO HN,LU HZ,CAO B,et al. Clinical findings in 111 cases of influenza A(H7N9)virus infection[J]. N Engl J Med,2013,368(24):2277-2285.

[10] LI LJ. Artificial liver[M]. Hangzhou:Zhejiang University Press,2012.(in Chinese)李兰娟．人工肝脏[M]．杭州:浙江大学出版社，2012.

[11] XU KJ,CAI HL,SHEN YH,et al. Management of corona virus disease-19(COVID-19):The Zhejiang experience[J]. J Zhejiang Univ(Med Sci),2020,49(2):147-157.(in Chinese)徐凯进，蔡洪流，沈毅弘，等．2019冠状病毒病(COVID-19)诊疗浙江经验[J]．浙江大学学报(医学版)，2020,49(2):147-157.

施引文献

资源附件(0)

访问统计